With COVID cases on the rise in many countries, the race to find an effective vaccine is becoming a more pressing concern ...
Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...
A summer wave of cases locally and across the country may be on the decline and a vaccine targeting the latest variants is ...
Flu season approaches and there's a new COVID variant. The time to act is now, or soon, according to the two largest local ...
Pfizer and BioNTech said on Friday that a committee from the European Medicine Agency recommended marketing authorization for its Omicron adapted vaccine to prevent Covid-19, meaning the vaccine is ...
Pfizer PFE stock has risen 7.3% in the past three months compared with an increase of 2.9% for the industry. The stock has ...
ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial ...
Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use ...
The EMA has approved Penbraya for protection against invasive meningococcal disease and an update of the composition of two ...